BDNF biosensors for neurodegenerative disease

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-06-03 DOI:10.1016/j.cca.2025.120412

Tamara Nazar Saeed , Ali Fawzi Al-Hussainy , Gaurav Sanghvi , Suhas Ballal , Abhayveer Singh , A. Sabarivani , Swati Mishra , Jasur Rizaev , Sada Ghalib Taher , Mariem Alwan , Mahmood Jawad , Hiba Mushtaq

{"title":"BDNF biosensors for neurodegenerative disease","authors":"Tamara Nazar Saeed , Ali Fawzi Al-Hussainy , Gaurav Sanghvi , Suhas Ballal , Abhayveer Singh , A. Sabarivani , Swati Mishra , Jasur Rizaev , Sada Ghalib Taher , Mariem Alwan , Mahmood Jawad , Hiba Mushtaq","doi":"10.1016/j.cca.2025.120412","DOIUrl":null,"url":null,"abstract":"<div><div>The brain-derived neurotrophic factor (BDNF) is essential for neuronal health and function. Dysregulated BDNF levels have been correlated with the etiology of several neurological disorders, including Alzheimer’s and Parkinson’s diseases. Recently, biomarkers of central nervous system (CNS) inflammatory responses have been discovered in a variety of body fluids, including blood, cerebrospinal fluid (CSF), and tears. Personalized medicine and screening programs will become feasible once biosensing technologies advance sufficiently and are widely implemented in communities. This multidisciplinary review provides an overview of the molecular structure and synthesis of BDNF, emphasizing the complexity and intricate regulation of this crucial neurotrophic factor, as well as exploring the potential of BDNF as a biomarker for neurological conditions. It focuses on its role in disease progression and its utility in early disease detection using aptasensors and immunosensors. We also discuss the challenges associated with utilizing BDNF as a biomarker, such as its complex regulation and the need for sensitive and specific detection methods by electrochemical and optical transducers. Furthermore, we highlight the potential of biosensors to overcome these challenges by enabling real-time, non-invasive, and point-of-care (POC) monitoring of BDNF levels.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"576 ","pages":"Article 120412"},"PeriodicalIF":3.2000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125002918","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The brain-derived neurotrophic factor (BDNF) is essential for neuronal health and function. Dysregulated BDNF levels have been correlated with the etiology of several neurological disorders, including Alzheimer’s and Parkinson’s diseases. Recently, biomarkers of central nervous system (CNS) inflammatory responses have been discovered in a variety of body fluids, including blood, cerebrospinal fluid (CSF), and tears. Personalized medicine and screening programs will become feasible once biosensing technologies advance sufficiently and are widely implemented in communities. This multidisciplinary review provides an overview of the molecular structure and synthesis of BDNF, emphasizing the complexity and intricate regulation of this crucial neurotrophic factor, as well as exploring the potential of BDNF as a biomarker for neurological conditions. It focuses on its role in disease progression and its utility in early disease detection using aptasensors and immunosensors. We also discuss the challenges associated with utilizing BDNF as a biomarker, such as its complex regulation and the need for sensitive and specific detection methods by electrochemical and optical transducers. Furthermore, we highlight the potential of biosensors to overcome these challenges by enabling real-time, non-invasive, and point-of-care (POC) monitoring of BDNF levels.

查看原文本刊更多论文

神经退行性疾病的BDNF生物传感器

脑源性神经营养因子（BDNF）对神经元的健康和功能至关重要。BDNF水平失调与几种神经系统疾病的病因有关，包括阿尔茨海默病和帕金森病。最近，在多种体液中发现了中枢神经系统（CNS）炎症反应的生物标志物，包括血液、脑脊液（CSF）和眼泪。一旦生物传感技术充分发展并在社区中广泛实施，个性化医疗和筛查计划将成为可能。这篇多学科综述综述了BDNF的分子结构和合成，强调了这一重要神经营养因子的复杂性和复杂的调控，并探索了BDNF作为神经系统疾病生物标志物的潜力。它侧重于它在疾病进展中的作用，以及它在使用适体传感器和免疫传感器的早期疾病检测中的效用。我们还讨论了利用BDNF作为生物标志物所面临的挑战，例如其复杂的调控以及对电化学和光学传感器灵敏和特异性检测方法的需求。此外，我们强调了生物传感器的潜力，通过实现实时、无创和即时（POC）监测BDNF水平来克服这些挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.